Clinical Trials Directory

Trials / Completed

CompletedNCT01744431

Can Thrombin Generation Measurement Predict the Risk of Venous Thromboembolism in Acute Ill Patients

Status
Completed
Phase
Study type
Observational
Enrollment
400 (actual)
Sponsor
HaEmek Medical Center, Israel · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Can thrombin generation measurement predict the risk of venous thromboembolism in acute ill patients Traditional coagulation tests do not assess the whole coagulation system. Thrombin generation assays measure the ability of plasma sample to generate thrombin following in vitro activation of coagulation. In contrast to the classical clotting assays, thrombin generation reflects and integrates all pro and anticoagulant reactions that regulate the formation and inhibition of thrombin. The aim of our study is to investigate whether thrombin generation would be able to predict a hypercoagulable state in acute ill patients admitted in the internal medical departments and how it correlates with the Padua prediction score, a score that could assists the risk for venous thromboembolism in hospitalized medical patients. In total 300 patients are planned for inclusion in this trial. After signing an informed consent a blood sample will be obtained from each participant. We will measure the thrombin generation over time in plasma assessed by the calibrated automated thrombogram (CAT).

Conditions

Timeline

Start date
2012-12-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2012-12-06
Last updated
2015-12-16

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01744431. Inclusion in this directory is not an endorsement.